このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Cue Biopharma 将来の成長
Future 基準チェック /26
Cue Biopharmaは、34.9%と64.4%でそれぞれ年率34.9%で利益と収益が成長すると予測される一方、EPSはgrowで35.5%年率。
主要情報
34.9%
収益成長率
35.5%
EPS成長率
Biotechs 収益成長 | 24.7% |
収益成長率 | 64.4% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | 06 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 19 | -70 | N/A | -86 | 3 |
12/31/2025 | 15 | -63 | N/A | -60 | 4 |
12/31/2024 | 11 | -52 | N/A | -49 | 4 |
3/31/2024 | 7 | -50 | -39 | -39 | N/A |
12/31/2023 | 5 | -51 | -40 | -40 | N/A |
9/30/2023 | 4 | -52 | -40 | -40 | N/A |
6/30/2023 | 2 | -52 | -39 | -39 | N/A |
3/31/2023 | 0 | -52 | -41 | -41 | N/A |
12/31/2022 | 1 | -53 | -42 | -42 | N/A |
9/30/2022 | 9 | -47 | -42 | -42 | N/A |
6/30/2022 | 12 | -49 | -42 | -42 | N/A |
3/31/2022 | 14 | -46 | -39 | -39 | N/A |
12/31/2021 | 15 | -44 | -40 | -39 | N/A |
9/30/2021 | 7 | -47 | -36 | -35 | N/A |
6/30/2021 | 5 | -44 | -38 | -36 | N/A |
3/31/2021 | 4 | -44 | -35 | -33 | N/A |
12/31/2020 | 3 | -45 | -33 | -32 | N/A |
9/30/2020 | 4 | -43 | -32 | -32 | N/A |
6/30/2020 | 4 | -40 | -34 | -33 | N/A |
3/31/2020 | 4 | -38 | -33 | -33 | N/A |
12/31/2019 | 3 | -37 | -31 | -31 | N/A |
9/30/2019 | 3 | -39 | -28 | -28 | N/A |
6/30/2019 | 2 | -45 | -26 | -25 | N/A |
3/31/2019 | 2 | -43 | -26 | -25 | N/A |
12/31/2018 | 1 | -39 | -28 | -26 | N/A |
9/30/2018 | 1 | -38 | -26 | -24 | N/A |
6/30/2018 | 0 | -30 | -23 | -22 | N/A |
3/31/2018 | N/A | -27 | -20 | -18 | N/A |
12/31/2017 | N/A | -23 | N/A | -12 | N/A |
9/30/2017 | N/A | -16 | N/A | -12 | N/A |
6/30/2017 | N/A | -13 | N/A | -10 | N/A |
3/31/2017 | N/A | -10 | N/A | -8 | N/A |
12/31/2016 | N/A | -8 | N/A | -6 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CUE今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CUE今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: CUE今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CUEの収益 ( 64.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: CUEの収益 ( 64.4% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CUEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です